Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628 1629
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19219972 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18005245 | LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND | Final Rejection | Eli Lilly and Company |
| 18550303 | HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18310238 | Niraparib Compositions | Non-Final OA | Merck Sharp & Dohme LLC |
| 19323465 | PHARMACEUTICAL COMPOSITION FOR HAILEY-HAILEY DISEASE AND USE THEREOF | Final Rejection | TANABE PHARMA CORPORATION |
| 18290772 | INHIBITING INTRACELLULAR PATHOGENS | Non-Final OA | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17595446 | DIETARY BUTYRATE AND ITS USES | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18263341 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17283217 | USE OF PDE9 INHIBITORS FOR TREATMENT | Non-Final OA | The Johns Hopkins University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy